Compare
Tango Therapeutics, Inc. vs Nuvation Bio Inc. vs Fortress Biotech, Inc. vs Journey Medical Corp
| Latest fiscal year | Tango Therapeutics, Inc. TNGX | Nuvation Bio Inc. NUVB | Fortress Biotech, Inc. FBIO | Journey Medical Corp DERM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $62.38M | $62.90M | $63.26M | $61.24M |
| Revenue growth (YoY) | +48.3% | +699.0% | +9.7% | +11.1% |
| Gross margin | n/a | n/a | 66.9% (computed) | 65.8% (computed) |
| Operating margin | -178.4% | -338.7% | -111.0% | -13.3% |
| Net margin | -162.9% | -325.3% | 10.8% | -18.7% |
| Net income | -$101.59M | -$204.63M | $6.82M | -$11.43M |
| EPS (Diluted) | -$0.87 | -$0.60 | -$0.07 | -$0.47 |
| Operating cash flow | -$138.89M | -$173.43M | -$65.78M | -$12.44M |
| Free cash flow | -$139.93M | n/a | n/a | n/a |
| Cash & equivalents | $112.28M | $164.09M | $79.38M | $24.09M |
| Total assets | $398.69M | $594.82M | $185.55M | $94.59M |
| Total liabilities | $52.51M | $289.11M | $123.36M | $62.74M |
| Shareholders' equity | $346.18M | $305.72M | $49.87M | $31.85M |
| Return on year-end equity | -29.3% | -66.9% | 13.7% | -35.9% |
| Shares outstanding | 135.94M | 337.84M | 31.36M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Tango Therapeutics, Inc. | Nuvation Bio Inc. | Fortress Biotech, Inc. | Journey Medical Corp |
|---|---|---|---|---|
| Latest | $62.38M Ended 2025-12-31 | $62.90M Ended 2025-12-31 | $63.26M Ended 2025-12-31 | $61.24M Ended 2025-12-31 |
| 1 year earlier | $42.07M Ended 2024-12-31 | $7.87M Ended 2024-12-31 | $57.67M Ended 2024-12-31 | $55.13M Ended 2024-12-31 |
| 2 years earlier | $36.53M Ended 2023-12-31 | $0 Ended 2023-12-31 | $84.51M Ended 2023-12-31 | $59.66M Ended 2023-12-31 |
| 3 years earlier | $24.86M Ended 2022-12-31 | n/a | $75.74M Ended 2022-12-31 | $71.00M Ended 2022-12-31 |
| 4 years earlier | $37.04M Ended 2021-12-31 | n/a | $68.79M Ended 2021-12-31 | $63.13M Ended 2021-12-31 |